Sastasundar Ventures Valuation
Is 533259 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 533259 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 533259's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 533259's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 533259?
Key metric: As 533259 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 533259's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | ₹13.09b |
| Market Cap | ₹10.32b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.9x |
| Enterprise Value/EBITDA | 17.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 533259's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.1x | ||
DENTALKART Vasa Denticity | 6x | n/a | ₹12.6b |
REMUS Remus Pharmaceuticals | 3.4x | n/a | ₹15.6b |
BALAXI Balaxi Pharmaceuticals | 1.6x | n/a | ₹4.1b |
QMSMEDI QMS Medical Allied Services | 1.5x | n/a | ₹2.0b |
533259 Sastasundar Ventures | 0.8x | 24.3% | ₹10.3b |
Price-To-Sales vs Peers: 533259 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (3.1x).
Price to Sales Ratio vs Industry
How does 533259's PS Ratio compare vs other companies in the IN Healthcare Industry?
| 9 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
MONOPHARMA Mono Pharmacare | 0.5x | n/a | US$7.71m |
539938 Medico Intercontinental | 0.7x | n/a | US$6.75m |
542934 Chandra Bhagat Pharma | 0.3x | n/a | US$6.14m |
530697 Zenlabs Ethica | 0.5x | n/a | US$3.11m |
| 9 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 533259 is good value based on its Price-To-Sales Ratio (0.8x) compared to the Indian Healthcare industry average (4.3x).
Price to Sales Ratio vs Fair Ratio
What is 533259's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 1.6x |
Price-To-Sales vs Fair Ratio: 533259 is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.